- Home
- AUTL vs TCI Comparison
AUTL vs TCI Comparison
Compare AUTL & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUTL | TCI |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.9M | 350.0M |
| IPO Year | 2025 | 1994 |
Fundamental Metrics
Financial Performance| Metric | AUTL | TCI |
|---|---|---|
| Price | $1.44 | $44.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 3.2K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 135.29 |
| EPS | N/A | ★ 0.02 |
| Revenue | $10,120,000.00 | ★ $49,060,000.00 |
| Revenue This Year | $80.32 | N/A |
| Revenue Next Year | $53.96 | N/A |
| P/E Ratio | ★ N/A | $2,276.50 |
| Revenue Growth | ★ 496.00 | 4.23 |
| 52 Week Low | $1.18 | $31.48 |
| 52 Week High | $2.70 | $59.65 |
Technical Indicators
Market Signals| Indicator | AUTL | TCI |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 58.71 |
| Support Level | $1.38 | $43.15 |
| Resistance Level | $1.52 | $47.90 |
| Average True Range (ATR) | 0.10 | 1.94 |
| MACD | -0.02 | -0.32 |
| Stochastic Oscillator | 11.59 | 26.37 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.